hotspot -WSS

hotspot

author：entertainment 2025-09-28 21:58:16 - browse：49

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： This gene therapy has record $4.25 million price. It's saved children.

entertainment

explore

WSS

Bring on the sabbaticals for nurses

Humana cuts profit projections as Medicare Advantage costs soar

Medicare Advantage today, explained in one chart

Eli Lilly, Pfizer, and others want in on the online prescription market

Testing GLP

This gene therapy has record $4.25 million price. It's saved children.

knowledge

hotspot

focus

In Memoriam: Notable people who died in 2023

The tragedy of Johnson & Johnson’s Covid vaccine

Jerome Adams on the need for new antivirals for Covid

Elizabeth Holmes banned from government health programs

Walensky prepares to leave CDC — and Congress — behind

Eli Lilly, Pfizer, and others want in on the online prescription market

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

After affirmative action ruling, medical educators look to 'holistic review'

CRISPR technology availability, affordability needs to be expanded

hotspot

Texas board proposes rules on abortion law emergency exemption

Asbestos ban is immediate, but health effects will linger for decades

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Yancopoulos of Regeneron works to expand Dupixent success

Biotech venture capitalists face new demands from investors

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

knowledge

entertainment

explore

hotspot